



Rabbit Anti-Human RANKL monoclonal antibody, clone S239 (CABT-ZB820)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Specificity	It reacts with Human RANKL
Target	TNFSF11
Immunogen	Recombinant Human RANKL/OPGL/TNFSF11/CD254 Protein
Isotype	IgG
Source/Host	Rabbit
Species Reactivity	Human
Clone	S239
Purification	Protein A purified
Conjugate	Unconjugated
Applications	ELISA(cap) We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB820 - CABT-ZB1110 This antibody will detect RANKL in antibody pair set. [ABPR-ZB401]
Preparation	This antibody was obtained from a rabbit immunized with purified, recombinant Human RANKL / OPGL / TNFSF11 / CD254.
Format	Purified, Liquid
Concentration	Lot specific
Size	50 µL, 100 µL, 1 mL

Buffer	PBS
Preservative	None
Storage	This antibody can be stored at 2°C-8°C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20°C to -80°C. Preservative-Free. Avoid repeated freeze-thaw cycles.
Ship	Wet ice

BACKGROUND

Introduction Tumor necrosis factor ligand superfamily member 11, also known as Receptor activator of nuclear factor kappa-B ligand, Osteoprotegerin ligand, TNFSF11, RANKL, TRANCE, OPGL and CD254, is a single-pass type II membrane protein that belongs to the tumor necrosis factor family. The receptor activator of nuclear factor-kappaB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. RANK and RANKL are key regulators of bone remodeling and regulate T cell/dendritic cell communications, and lymph node formation. Moreover, RANKL and RANK are expressed in mammary gland epithelial cells and control the development of a lactating mammary gland during pregnancy. Genetically, RANKL and RANK are essential for the development and activation of osteoclasts and bone loss in response to virtually all triggers tested. Inhibition of RANKL function via the natural decoy receptor osteoprotegerin (OPG, TNFRSF11B) prevents bone loss in postmenopausal osteoporosis and cancer metastases. Importantly, RANKL appears to be the pathogenetic principle that causes bone and cartilage destruction in arthritis. RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology and disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy.

Keywords TNFSF11; tumor necrosis factor (ligand) superfamily; member 11; ODF

GENE INFORMATION

Synonyms TNFSF11; tumor necrosis factor (ligand) superfamily; member 11; ODF; OPGL; sOdf; CD254; OPTB2; RANKL; TRANCE; hRANKL2; tumor necrosis factor ligand superfamily member 11; osteoprotegerin ligand; osteoclast differentiation factor; TNF-related activation-induced cytokine; receptor activator of nuclear factor kappa B ligand; receptor activator of nuclear factor kappa-B ligand

Entrez Gene ID [8600](#)

UniProt ID [O00300](#)